Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTLF NASDAQ:LONA NASDAQ:ONCY NASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$9.86-0.7%$10.66$8.67▼$20.98$92.60M-0.0124,843 shs33,378 shsLONAAthira Pharma$9.81+1.4%$9.75$2.73▼$14.21$92.16M1.9863,707 shs51,230 shsONCYOncolytics Biotech$0.90+11.1%$0.94$0.33▼$1.51$107.42M1.021.26 million shs1.65 million shsTXMDTherapeuticsMD$2.11$2.10$0.98▼$2.95$24.42M0.5854,713 shs27,201 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands-1.39%-0.70%+5.86%-34.46%-31.89%LONAAthira Pharma-6.39%-4.16%+16.09%+66.44%+966,999,900.00%ONCYOncolytics Biotech+0.10%+4.55%-21.33%-27.00%+93.67%TXMDTherapeuticsMD-0.47%+3.43%-3.65%-6.22%+45.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$9.86-0.7%$10.66$8.67▼$20.98$92.60M-0.0124,843 shs33,378 shsLONAAthira Pharma$9.81+1.4%$9.75$2.73▼$14.21$92.16M1.9863,707 shs51,230 shsONCYOncolytics Biotech$0.90+11.1%$0.94$0.33▼$1.51$107.42M1.021.26 million shs1.65 million shsTXMDTherapeuticsMD$2.11$2.10$0.98▼$2.95$24.42M0.5854,713 shs27,201 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands-1.39%-0.70%+5.86%-34.46%-31.89%LONAAthira Pharma-6.39%-4.16%+16.09%+66.44%+966,999,900.00%ONCYOncolytics Biotech+0.10%+4.55%-21.33%-27.00%+93.67%TXMDTherapeuticsMD-0.47%+3.43%-3.65%-6.22%+45.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTLFFitLife Brands 2.25Hold$21.50118.05% UpsideLONAAthira Pharma 2.40Hold$15.0052.91% UpsideONCYOncolytics Biotech 2.75Moderate Buy$8.50844.44% UpsideTXMDTherapeuticsMD 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TXMD, LONA, ONCY, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026LONAAthira Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/26/2026ONCYOncolytics Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/11/2026LONAAthira Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/7/2026FTLFFitLife Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/6/2026TXMDTherapeuticsMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)4/2/2026FTLFFitLife Brands Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.003/27/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)2/27/2026LONAAthira Pharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTLFFitLife Brands$90.85M1.02$1.14 per share8.64$4.83 per share2.04LONAAthira PharmaN/AN/AN/AN/A$5.25 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ATXMDTherapeuticsMD$3.35M7.28$0.05 per share45.44$2.33 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTLFFitLife Brands$6.33M$0.6016.328.57N/A6.64%18.31%8.21%N/ALONAAthira Pharma-$105.61M-$5.21N/AN/AN/AN/A-381.01%-225.74%N/AONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-2,185.97%-321.54%7/31/2026 (Estimated)TXMDTherapeuticsMD-$570K$0.0635.17N/AN/A5.34%0.32%0.23%N/ALatest TXMD, LONA, ONCY, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FTLFFitLife Brands$0.14$0.17+$0.03$0.17N/A$25.33 million5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A5/12/2026Q1 2026TXMDTherapeuticsMD-$6.1250$0.01+$6.1350$0.01$19.77 million$0.72 million5/7/2026Q1 2026LONAAthira PharmaN/A-$1.73N/A-$1.73N/AN/A3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/30/2026Q4 2025TXMDTherapeuticsMD-$6.1250-$0.0530+$6.0720-$0.05$19.77 million$0.89 million3/26/2026Q4 2025LONAAthira PharmaN/A-$18.90N/A-$18.90N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFTLFFitLife BrandsN/AN/AN/AN/AN/ALONAAthira PharmaN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTLFFitLife Brands0.781.520.49LONAAthira PharmaN/A10.3810.38ONCYOncolytics BiotechN/A1.381.38TXMDTherapeuticsMDN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTLFFitLife Brands2.32%LONAAthira Pharma57.12%ONCYOncolytics Biotech6.82%TXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipFTLFFitLife Brands61.40%LONAAthira Pharma25.73%ONCYOncolytics Biotech0.10%TXMDTherapeuticsMD1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableLONAAthira Pharma409.39 million6.98 millionN/AONCYOncolytics Biotech30119.35 million119.24 millionNot OptionableTXMDTherapeuticsMD42011.57 million11.38 millionOptionableTXMD, LONA, ONCY, and FTLF HeadlinesRecent News About These CompaniesTherapeuticsMD Reports Quarterly Profit, Evaluates Strategic AlternativesMay 12, 2026 | tipranks.comTherapeuticsMD Announces First Quarter 2026 Financial ResultsMay 12, 2026 | businesswire.comTherapeuticsMD Inc. stock outperforms competitors on strong trading dayApril 6, 2026 | marketwatch.comTherapeuticsMD Narrows 2025 Loss, Advances Royalty StrategyApril 2, 2026 | theglobeandmail.comTherapeuticsMD Explains Brief Delay In Annual FilingApril 1, 2026 | tipranks.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | finance.yahoo.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | businesswire.comTherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 SharesDecember 30, 2025 | insidertrades.comTherapeuticsMD approves key proposals at annual meetingDecember 16, 2025 | msn.comTherapeuticsMD: Q3 Earnings SnapshotNovember 13, 2025 | timesunion.comTTherapeuticsMD Reports Q3 2025 Financial ResultsNovember 13, 2025 | msn.comTherapeuticsMD Announces Third Quarter 2025 Financial ResultsNovember 12, 2025 | businesswire.comTherapeuticsMD Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comTherapeuticsMD: Q2 Earnings SnapshotAugust 12, 2025 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2025 Financial ResultsAugust 12, 2025 | businesswire.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 16, 2025 | marketwatch.comMarlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street JournalJune 29, 2025 | wsj.comMayne Pharma Files Legal Complaint Against TherapeuticsMDJune 1, 2025 | tipranks.comTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comTherapeuticsMD Inc. stock rises Monday, still underperforms marketMay 12, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTXMD, LONA, ONCY, and FTLF Company DescriptionsFitLife Brands NASDAQ:FTLF$9.86 -0.07 (-0.70%) Closing price 04:00 PM EasternExtended Trading$9.90 +0.04 (+0.35%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Athira Pharma NASDAQ:LONA$9.81 +0.14 (+1.45%) Closing price 04:00 PM EasternExtended Trading$9.78 -0.03 (-0.25%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Oncolytics Biotech NASDAQ:ONCY$0.90 +0.09 (+11.07%) Closing price 04:00 PM EasternExtended Trading$0.92 +0.02 (+2.00%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.TherapeuticsMD NASDAQ:TXMD$2.11 0.00 (0.00%) As of 04:00 PM EasternTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
